Athira Pharma Inc To Discuss The ACT-AD Results Transcript
Welcome to Athira Pharma's conference call to top-line results from the ACT-AD clinical study. This conference call is being recorded today, June 22, 2022. I would like to turn the conference call over to Julie Rathbun, Head of Investor and Public Relations at Athira Pharma.
Thank you, operator. Earlier this morning, we issued the top-line results from the Phase 2 ACT-AD proof-of-concept study of fosgonimeton in mild-to-moderate Alzheimer's disease patients. This press release and presentation can be found on the Investors section of our website.
Before we begin, I'd like to remind you that during this call, we'll make -- management will make forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described here and, from time to time, in our SEC filings. Our results may differ materially from those projected on today's call. Athira is not under any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
